FKGK18|cas:1071001-09-6|西域试剂

FKGK18,99.0%

产品编号：Bellancom-115403| CAS NO：1071001-09-6| 分子式：C₁₆H₁₅F₃O| 分子量：280.28

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-115403		￥1500.00	杭州北京（现货）
Bellancom-115403		￥4800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FKGK18

产品介绍

FKGK18 是一种选择性的 group VIA calcium-independent phospholipase A₂ (GVIA iPLA₂) 抑制剂。FKGK18 是一种氟酮基化合物，对 iPLA₂β 和 iPLA₂γ 的 IC₅₀ 值为 50 nM 和 3 μM。FKGK18 可用于 β 细胞凋亡和糖尿病的研究。

生物活性

FKGK18 is a selective group VIA calcium-independent phospholipase A₂ (GVIA iPLA₂) inhibitor. FKGK18 is a fluoroketone (FK)-based compound with IC₅₀s of 50 nM and 3 μM for iPLA₂β and iPLA₂γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes.

体外研究

FKGK18 (1 nM; 1 h) inhibits glucose-stimulated insulin secretion (GSIS) and prostaglandin E2 (PGE2) generation.
FKGK18 (0.1-10 nM; 24 h) inhibits beta-cell apoptosis.
FKGK18 (0.1-10 μM; 24 h) affects immune cells function and influences B-cell survival.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Human pancreatic islets
Concentration:	1 nM
Incubation Time:	1 h
Result:	Inhibited GSIS from pancreatic islets, AA hydrolysis from beta-cells membranes and PGE2 generation. Penetrated islets and the beta-cells from islets.

Apoptosis Analysis

Cell Line:	INS-1 OE cells
Concentration:	0.1-10 nM
Incubation Time:	24 h
Result:	Inhibited beta-cells apoptosis induced by ER-stress.

Cell Viability Assay

Cell Line:	CD4⁺ T-cell and B-cell from 8–12-week-old NOD female mice
Concentration:	0.1-10 μM/L
Incubation Time:	24 h
Result:	Decreased TNF-α generation, reduced viability of B cell and antibody production.

体内研究
(In Vivo)

FKGK18 (20 mg/kg; i.p. three times per week from 10 days until euthanasia) reduces diabetes incidence.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	10-day-old female NOD mice
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; 20 mg/kg three times per week; from 10 days until euthanasia
Result:	Reduced diabetes incidence and maintained better glucose homeostasis.

体内研究

FKGK18 (20 mg/kg; i.p. three times per week from 10 days until euthanasia) reduces diabetes incidence.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	10-day-old female NOD mice
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; 20 mg/kg three times per week; from 10 days until euthanasia
Result:	Reduced diabetes incidence and maintained better glucose homeostasis.

体内研究

FKGK18 (20 mg/kg; i.p. three times per week from 10 days until euthanasia) reduces diabetes incidence.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	10-day-old female NOD mice
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; 20 mg/kg three times per week; from 10 days until euthanasia
Result:	Reduced diabetes incidence and maintained better glucose homeostasis.